Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding trial of deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis
2024-511330-13-00Phase 2Authorised
- Sponsor
- PureTech Health
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of deupirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by PureTech Health. Planned start May 2024; status: authorised.
02
Drugs
deupirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2024-511330-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511330-13-00.